Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
11:00-11:15 | 11:00-11:15 |
Mechanism, Glucose Lowing Efficacy and Safety of GLP-1RA |
Yingsheng Zhou | |
11:15-11:22 | 11:15-11:22 |
Discussion |
||
11:22-11:37 | 11:22-11:37 |
Clinical Evidence of Cardiovascular Benefit in GLP-1RA |
Jianzhong Xiao | |
11:37-11:44 | 11:37-11:44 |
Discussion |
||
11:44-11:59 | 11:44-11:59 |
GLP-1RA and Heart Failure |
Xiaowei Yan | Peking Union Medical College Hospital |
11:59-12:06 | 11:59-12:06 |
Discussion |
||
12:06-12:21 | 12:06-12:21 |
GLP-1RA:Potential Mechanism of Cardiovascular Protection Effects and Its Evolutional Role in Guidelines |
gong qiuhong | Fuwai Hospital |
12:21-12:30 | 12:21-12:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
14:00-14:15 | 14:00-14:15 |
Mechanism, Glucose Lowing Efficacy and Safety of SGLT2i |
Hongyu Kuang | |
14:15-14:22 | 14:15-14:22 |
Discussion |
||
14:22-14:37 | 14:22-14:37 |
SGLT2i and Clinical Evidence of Cardiovascular Benefit |
Yanbing Li | |
14:37-14:44 | 14:37-14:44 |
Discussion |
||
14:44-14:59 | 14:44-14:59 |
SGLT2i:Potential Mechanism of Cardiovascular Protection Effects and Evolutional Role in Guidelines |
Xinhua Xiao | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
14:59-15:06 | 14:59-15:06 |
Discussion |
||
15:06-15:21 | 15:06-15:21 |
SGLT2i and Heart Failure |
Miao Yu | Peking Union Medical College Hospital |
15:21-15:30 | 15:21-15:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
16:00-16:15 | 16:00-16:15 |
Interaction of Diabetic Nephropathy and ASCVD in Diabetes |
Hang Li | |
16:15-16:22 | 16:15-16:22 |
Discussion |
||
16:22-16:37 | 16:22-16:37 |
Clinical Evidence of the Renal Benefits of GLP-1RA |
Pei Yu | |
16:37-16:44 | 16:37-16:44 |
Discussion |
||
16:44-16:59 | 16:44-16:59 |
Clinical Evidence of the Renal Benefit of SGLT2i |
Yan Qin | |
16:59-17:06 | 16:59-17:06 |
Discussion |
||
17:06-17:21 | 17:06-17:21 |
Potential Mechanism of the Cardiovascular Benefits of GLP-1RA & SGLT2i: A Renal-Centric Standpoint |
Zhihong Wang | |
17:21-17:30 | 17:21-17:30 |
Discussion |
Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
---|---|---|---|---|
19:00-19:15 | 19:00-19:15 |
CVOTs in the Field of Diabetes:The Known and Unknown |
Miao Yu | Peking Union Medical College Hospital |
19:15-19:30 | 19:15-19:30 |
Discussion |
||
19:30-19:45 | 19:30-19:45 |
Evidence of GLP-1RA & SGLT2i in the Primary Prevention for Cardiovascular Events |
Qifu Li | The First Affiliated Hospital of Chongqing Medical University |
19:45-20:00 | 19:45-20:00 |
Discussion |
||
20:00-20:15 | 20:00-20:15 |
Evidence for Combined Therapy with GLP-1RA & SGLT2i |
Yan Li | |
20:15-20:30 | 20:15-20:30 |
Discussion |
||
20:30-20:45 | 20:30-20:45 |
Paradigm Shift in Diabetes Management |
Linong Ji | Peking University People’s Hospital |
20:45-21:00 | 20:45-21:00 |
Discussion |